Visiting Fellowship in Transcranial Magnetic Stimulation
January 28-29, 2012; April 28-29, 2012; July 21-22, 2012; October 27-28, 2012
Duke University Medical Center
Bryan Research Building – 3rd Floor Conference Room 301B
Sponsored by the Duke University School of Medicine and the North Carolina Psychological
Association
Course Description
The course, sponsored by the Duke University School of Medicine and the North Carolina Psychological
Association, includes hands-on administration of Transcranial Magnetic Stimulation (TMS). In October
2008, the FDA approved TMS for treatment of major depression. Didactic sessions with the TMS faculty
of Duke University and Columbia University cover all topics relevant to running a TMS clinical service and
a TMS research lab, including: new developments in motor threshold determination, treatment technique,
stimulus dosing, risks, complications and contraindications, safety screening and concurrent medications,
post TMS management and continuation treatment, clinical and non-clinical research applications, TMS
research study designs, and emerging brain stimulation techniques (e.g., magnetic seizure therapy).
Target Audience
This activity is designed for psychiatrists, psychologists, and researchers who wish to enhance their knowledge
of TMS and the related brain stimulation techniques.
Learning Objectives
At the conclusion of this activity, participants should be able to:
 State the rationale for the use of TMS in depression, anxiety disorders, and schizophrenia based on
current and previous research on the topics
 Compare and contrast two differences in cortical excitability and implications for depression, anxiety
disorders, and schizophrenia
 Apply the FDA indication for use of TMS in a clinical setting
 Name the two main components of transcranial magnetic stimulation devices
 Operate the TMS device and correctly use it to determine the motor threshold and optimal site of two
participants
 Design a screening protocol to evaluate for TMS contraindications and a seizure protocol for
management of patients during TMS administration
Registration
The course is open to physicians, researchers and other professionals and trainees, from the U.S. and abroad.
This program is sponsored by the Duke University School of Medicine and the North Carolina Psychological
Association. The course registration fee is $1,500 and it is payable by check or online credit card (fee
applies). Fee may be waived for full-time Duke faculty and trainees, please inquire when registering. Payment
is due by one month before the course start date. A written notice of cancellation must be received 30 days
prior to the start of this activity. A 10% cancellation fee will be assessed at that time; after that date,
cancellation requests cannot be honored. Please contact Rosa Jou-Zhang at rosa.jouzhang@duke.edu or
919-681-6165 for more information.
1
Accreditation
The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The Duke University School of Medicine designates this live activity for a maximum of 14 AMA PRA Category
1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the
activity.
How to Receive CME Credit
In order to receive CME credit, participants must sign-in, review the CME information (accreditation, learning
objectives, faculty disclosures, etc.) and attend the CME activity. Participants should also complete the activity
evaluation form and return it to the appropriate representative following the CME activity.
Continuing Education Statement
The Visiting Fellowship in TMS is co-sponsored by the North Carolina Psychological Association and the Duke
University School of Medicine. The North Carolina Psychological Association is approved by the American
Psychological Association to sponsor continuing education for psychologists. The North Carolina
Psychological Association maintains responsibility for this program and its content. This program is offered for
14 hours of continuing education credit.
Attendance Requirements
To receive credit, you must be present for the entire 2 days and you must sign the sign-in and sign-out sheets
each day. No credit will be given to participants who are more than 15 minutes late at the beginning of the
morning and afternoon sessions. No credit will be given to participants who leave before the close of the 2-day
fellowship
Staff and Content Validation Reviewer Disclosure
The staff involved with this activity and any content validation reviewers of this activity have reported no
relevant financial relationships with commercial interests.
Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of
Medicine implemented mechanisms, prior to the planning and implementation of this CME activity, to identify
and resolve conflicts of interest for all individuals in a position to control content of this CME activity.
Planning Committee/Faculty Disclosure
The following speakers and/or planning committee members have indicated they have no relationship(s) with
industry to disclose relative to the content of this CME activity:




Franziska M. Korb, PhD
Bruce M. Luber, PhD
Antonio Mantovani, MD, PhD
Angel V. Peterchev, PhD
The following speaker/planning committee member has indicated that s/he has relationship(s) with industry to
disclose:

Andrew Krystal, MD serves as Principal Investigator for Abbott Laboratories, GSK, Merck, Pfizer,
Philips Medical Systems, Sepracor, Takeda, Cephalon, Somaxon; serves as consultant for Abbott
Laboratories, Eli Lilly, Philip Medical Systems, Sepracor, Takeda, Somaxon; serves as an Advisory
Board Member for GSK, Merck, Pfizer, Sanofi-Aventis, Cepahlon
2

Sarah H. Lisanby, MD serves as Principal Investigator for Magstim, Magventure, Brainsway,
Cyberonics, Neuronetics, ANS/St. Jude Medical
Disclaimer
The information provided at this CME activity is for continuing medical education purposes only and is not
meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment
options of a specific patient’s medical condition.
Unapproved Use Disclosure
Duke School of Medicine requires CME faculty (speakers) to disclose to attendees when products or
procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved);
and any limitations on the information that is presented, such as data that are preliminary or that represent
ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for
continuing medical education and is not intended to promote off-label use of these medications. If you have
questions, contact the medical affairs department of the manufacturer for the most recent prescribing
information. Faculty will be discussing information about pharmaceutical agents that is outside of U.S. Food
and Drug Administration approved labeling.
The following off-label uses are discussed:
TMS for depression in patients who has failed to respond to more than a single medication trial, and use of
TMS in the treatment of other psychiatric disorders (e.g. bipolar disorder, anxiety disorders, and
schizophrenia).
Faculty
Sarah H. Lisanby, MD – Activity Medical Director
Chair, Department of Psychiatry and Behavioral Sciences
Duke University
lisan001@win.duke.edu
919-684-5616
Dr. Lisanby earned her BS in mathematics and psychology magna cum laude at Duke University and her MD
at Duke University School of Medicine in Durham, North Carolina. After graduating, she completed a
residency in psychiatry at Duke University Medical Center, where she served as Executive Chief Resident. Her
postdoctoral fellowship in affective disorders research and geriatric psychiatry was conducted at Columbia
University. After serving as Brain Stimulation Division Director at Columbia University, she became chair of
psychiatry at Duke in October 2010. She became a leader in the field of TMS when her research team
innovated the use of TMS to perform convulsive therapy – a procedure termed Magnetic Seizure Therapy
(MST).
Franziska M. Korb, PhD
Postdoctoral Associate (Egner Lab)
Center for Cognitive Neuroscience
Duke University
franziska.korb@duke.edu
919-684-1034
Dr. Korb received her Pre-Diploma (B.Sc.) and Diploma (M.Sc.) in Psychology at the University of Leipzig,
Germany. For the research she conducted at the Max Planck Institute of Human Cognitive and Brain Sciences
Leipzig she earned her PhD in Psychology from the University of Leipzig. Before coming to Duke she worked
as a postdoctoral research associate at the Neurology Department of the University Clinic Cologne.
Andrew D. Krystal, MD
Professor of Psychiatry and Behavioral Sciences
Duke University
andrew.krystal@duke.edu
919-684-2057
3
Dr. Krystal received his training at the Duke University School of Medicine, finishing in 1987 before doing
residency in Psychiatry and Fellowships in Clinical Neurophysiology and Clinical Research Methodology. His
focus is on understanding the pathophysiology of sleep disorders and mood disorders and improving the
treatment of these conditions. He has published over 150 papers including work on optimizing ECT stimulus
intensity, the Neuronetics rTMS trial, and on the effects of TMS on craving for cigarettes. He is Past-President
and sits on the Board of Directors of the International Society for ECT and Neurostimulation. He is working
with Dr. Lisanby in developing the clinical and clinical research TMS program at Duke.
Antonio Mantovani, MD, PhD – Activity Co-Director
Associate Research Scientist
Columbia University
am2518@columbia.edu
212-543-6081
Dr. Mantovani completed medical training at Rome University and psychiatry training at Siena University.
Under the mentorship of Dr. Simone Rossi at Siena University, Dr. Mantovani received his PhD in Applied
Neurological Sciences. His graduate work focused on neurophysiological correlates of psychiatric disorders. At
Columbia University, he designs and conducts open and sham-controlled trials of Transcranial Magnetic
Stimulation (TMS) in the treatment of Obsessive Compulsive Disorder, Tourette Syndrome, Panic Disorder,
Depersonalization Disorder, and Major Depression.
Bruce M. Luber, PhD
Associate Professor of Psychiatry and Behavioral Sciences
Duke University
bruce.luber@duke.edu
919-681-9876
Dr. Luber received his PhD in experimental psychology from NYU, researching spatial attention using
magnetoencephalopgraphy (MEG). His post-doctorate work at Columbia University/NY State Psychiatric
Institute focused on the electrophysiology of memory and of ECT. He joined Dr. Holly Lisanby in the then new
field of transcranial magnetic stimulation (TMS) at Columbia in 1995. With Dr. Lisanby and collaborators he
researched the cortical mechanisms underlying working memory, conditioned learning, pain, deception, and
self-recognition. His primary focus is on the use of TMS to explore executive function and memory, and its
applications to geriatric psychiatry. He was on the faculty at Columbia University until November 2010 when
he moved to Duke University.
Angel V. Peterchev, PhD
Assistant Professor of Psychiatry and Behavioral Sciences, and Biomedical Engineering
Duke University
angel.peterchev@duke.edu
919-684-0383
Dr. Peterchev received the A.B. degree in physics and engineering sciences from Harvard University in 1999
and the M.S. and Ph.D. degrees in electrical engineering with a graduate-level minor in cognitive neuroscience
from the University of California at Berkeley in 2002 and 2005, respectively. He completed postdoctoral
training in TMS at Columbia University in 2007, and remained on the faculty there until the end of 2010 when
he moved to Duke University. Dr. Peterchev’s current research focuses on the development and modeling of
technology and application paradigms for transcranial brain stimulation, including TMS, electroconvulsive
therapy (ECT), magnetic seizure therapy (MST), and the integration of TMS with functional magnetic
resonance imaging (fMRI) and electroencephalography (EEG). The ultimate clinical goal of his work is to make
transcranial stimulation techniques robustly effective and safe.
For more information or to register, please contact
Rosa Jou-Zhang
rosa.jouzhang@duke.edu
Ph: 919-681-6165
Fax: 919-681-9962
4
or visit the Duke CME website at
http://cmetracker.net/DUKE/Courses.html
TMS CME AGENDA
Day
Saturday
Time
Event
Faculty
Location
8:30-9:00 am Breakfast
BRB – Rm 301B
9:00-10:00 am TMS as tool in Neuroscience
SHL
BRB – Rm 301B
10:00-11:00 am Treatment technique-Stimulus Dosing-Study Design
SHL
BRB – Rm 301B
BREAK
Regulatory Statements: IRB, IDE, FDA, Guidelines11:00-11:30 am
SHL
BRB – Rm 301B
ISTS consensus statement
11:30-12:30 pm Magnetic Seizure Therapy (MST)
SHL
BRB – Rm 301B
12:30-1:30 pm Lunch Break
1:30-2:30 pm Mechanisms of action: Physics of TMS
AVP
BRB – Rm 301B
2:30-3:30 pm TMS and Motor Cortex Excitability
AM
BRB – Rm 301B
BREAK
Hands-on: Motor Threshold determination with
FMK/AM BRB – Rm 359/361
research device + Robot Arm Exhibit
3:30-5:00 pm
Hands-on: Motor Threshold determination with
ADK
Erwin Sq, St 340
clinical device
Sunday
Breakfast
Hands-on: TMS device set-up and motor threshold
practice with research device
9:00-11:00 am
Hands-on: TMS device set-up and motor threshold
practice with clinical device
11:00-12:00pm Use of Imaging in TMS
12:00-1:00 pm Lunch Break
1:00-2:30 pm TMS and Mood Disorders
2:30-3:30 pm TMS and Anxiety Disorders and Schizophrenia
BREAK
Risks, Complications and Contraindications-Safety
3:30-4:00 pm Screening and Concurrent Medications;
Post TMS Management-Continuation Treatment
General Discussion, Q&A, Course Wrap-up and
4:00-5:00 pm
Completion of Course Evaluation
BRB – Rm 301B
8:30-9:00 am
Faculty Key
SHL: Sarah H. Lisanby, MD
BML: Bruce M. Luber, PhD
AVP: Angel V. Peterchev, PhD
AM/BML BRB – Rm 359/361
ADK
Erwin Sq, St 340
BML
BRB – Rm 301B
AM
AM
BRB – Rm 301B
BRB – Rm 301B
AM
BRB – Rm 301B
SHL/AM
BRB – Rm 301B
AM: Antonio Mantovani, MD, PhD
ADK: Andrew D. Krystal, MD
FMK: Franziska M. Korb, PhD
Locations:
Bryan Research Building (BRB)
3rd Floor Conference Room #301B
311 Research Drive
Durham, NC 27710
Link to Map: http://www.map.duke.edu/search?q=bryan+research+building
Erwin Square Tower
2200 West Main Street, Suite 340
Durham, NC 27705
Link to map: http://maps.duke.edu/building/241
5